Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
生化基因生化基因(US:BIIB) Businesswire·2026-07-14 21:16

公司信息 - 公司为Akamai，是一家提供网络安全和内容分发网络服务的科技公司 [1]

Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease - Reportify